|
Summary
April 2007, Vol. 8, No. 6, Pages 745-758
, DOI 10.1517/14656566.8.6.745
Review of long-acting stimulants in the treatment of attention deficit hyperactivity disorderRichard H WeislerAdjunct Associate Professor of Psychiatry and Adjunct Professor of Psychiatry, Duke University Medical Center, Durham, NC and the University of North Carolina at Chapel Hill Departments of Psychiatry700 Spring Forest, Suite 125, Raleigh, NC 27609, USA. rweisler@aol.com A number of long-acting medications for the treatment of attention deficit hyperactivity disorder (ADHD) have recently been developed and approved for use in the US. These compounds are intended to optimize and maintain ADHD symptom control throughout the day, while eliminating problems associated with short-acting medications, such as the need for in-school, midday or multiple daily doses. Recent reports confirm that the safety and tolerability of long-acting medications are similar to those of short-acting medications, although long-acting medications appear to have a lower risk of abuse and diversion and may be associated with significant improvements in medication adherence. Distinctions can be made among the long-acting medications with regard to the onset, magnitude and duration of their clinical effects. Recognition of these differences is important for individualizing treatment for patients with ADHD. Forward Links to Citing ArticlesRoss J. Baldessarini, Richard Perry, James Pike. (2008) Factors associated with treatment nonadherence among US bipolar disorder patients. Human Psychopharmacology: Clinical and Experimental 23:2, 95-105 Online publication date: 1-Apr-2008. CrossRef Users who read this article also read:
|
|





TOC Alert